Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Prostate Cancer treatment details. Biologic therapy. Chemotherapy. Memorial Sloan-Kettering Cancer Center, New York, NY, United States

Survival: 18.0 months
Toxicity Grade: 3
Treatments: Biologic therapy
Country: United States
City/State/Province: New York, NY
Hospital: Memorial Sloan-Kettering Cancer Center
Journal: Link
Date: 10/2009

This study involved 36 men with metastatic castration-resistant prostate cancer. The median age was 66 years old, with a range of 52-84 years.

Patients were administered a combination of the biologic therapy cetuximab, which is a monoclonal antibody that targets cancer cells to be killed by the immune system, and the chemotherapeutic agent doxorubicin.

Maximum toxicity observed in this study was of grade 3 and included nausea, fever, and vomiting. The most common complications were grade 1 fatigue (46% of patients) and grade 2 stomatitis (43%).

Median overall survival for this study was 18 months.

This study was supported by ImClone Systems, Inc., the makers of cetuximab (trade name Erbitux)

Correspondence: Dr. Susan F. Slovin; e-mail:

E-mail to a Friend Email Physician More Information